Form 4: LAVA Therapeutics Director Acquires Options in Recent Transaction
SEC Form 4 Filing
Director Christy J. Oliger acquired options to purchase 33,390 common shares of LAVA Therapeutics NV on February 13, 2025.
Summary
- On February 13, 2025, Christy J. Oliger, a director of LAVA Therapeutics N.V., acquired options to purchase 33,390 common shares.
- The exercise price of these options is $0.93 per share.
- The options vest on February 13, 2026, contingent upon continued service with the Issuer or its subsidiary.
- The options expire on February 12, 2035.
- Following the transaction, Oliger directly owns 33,390 common shares.
Sentiment
Score: 5
Explanation: The document is a neutral report of an insider transaction, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of earliest transaction: Christy J. Oliger acquired options to purchase common shares. |
| 02/13/2026 | Vesting date for the options, contingent upon continued service. |
| 02/12/2035 | Expiration date of the options. |
| 02/18/2025 | Date of signature by Attorney-in-Fact. |
Keywords
LAVA Therapeutics, Director, Options, Common Shares, Acquisition, Oliger, LVTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.